Trial Profile

Safety and Feasibility of a Malaria Transmission Model in Semi-immune Kenyan Adults Using Plasmodium Falciparum Sporozoites

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 27 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Malaria vaccine live attenuated-Sanaria (Primary) ; Malaria vaccine live unattenuated-Sanaria (Primary) ; Artemether/lumefantrine; Piperaquine; Primaquine; Pyrimethamine/sulfadoxine
Indications Falciparum malaria
Focus Adverse reactions; Therapeutic Use
Acronyms CHMI-TransMod

Most Recent Events

22 May 2024 Status changed from active, no longer recruiting to suspended.
28 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Aug 2026.
28 Nov 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com